marked.bio

TROP2 ADC · ADC

sacituzumab govitecan

8 active trials across 4 of our biomarkers, targeting TROP2. Not approved for any biomarker on marked.bio yet.

Also known as IMMU-132, Trodelvy.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 5 6 Phase 3
BRCA1/2 mutation 3 5 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
MSI-H / dMMR 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of sacituzumab govitecan.

  1. Gilead Sciences 2

Trials

8 of 12 trials shown

  1. Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

    Active, not recruiting Phase 3 Gilead Sciences Started 2023Primary completion 2028-04 NCT05840211

    sacituzumab govitecanpaclitaxelnab-paclitaxelcapecitabine

    …or-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

  2. Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

    Recruiting Phase 2 National Cancer Institute (NCI) Started 2026Primary completion 2029-04 NCT07504588

    Anti-VEGF Monoclonal Antibodybevacizumab FDA EUcarboplatingemcitabinepegylated liposomal doxorubicindoxorubicinsacituzumab govitecan

    Disease must be germline or somatic BRCA1 or BRCA2 mutated or homologous recombination deficiency test positive

    BRCA1/2 mutationRecurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma

  3. Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

    Not yet recruiting Phase 2 UNICANCER Started 2026Primary completion 2029-10 NCT07151586

    sacituzumab govitecantrastuzumab deruxtecan FDA EU

    HER2-low breast cancer, defined as either immunohistochemistry (IHC) 2+ / in situ hybridization (I…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer

  4. Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

    Not yet recruiting Phase 2 Fudan University Started 2026Primary completion 2027-06 NCT07368543

    sacituzumab govitecantrastuzumab deruxtecan FDA EU

    …etastatic breast cancer that is:HER2 IHC 1+ triple-negative breast cancer, or HR-positive/HER2-ultralow or HER2 IHC 1+ breast cancer.

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Metastatic Breast Cancer

  5. Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

    Recruiting Phase 2 British Columbia Cancer Agency Started 2025Primary completion 2027-05 NCT06665178

    sacituzumab govitecan

    Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer

  6. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

    Recruiting Phase 2 Reshma L. Mahtani, D.O. Started 2024Primary completion 2028-06 NCT06263543

    sacituzumab govitecan

    Histologically confirmed metastatic or advanced and unresectable breast cancer that is HER2 LOW/ULTRA LOW by local testing on either the primary or any metastatic site.

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer

  7. Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

    Recruiting Phase 2 German Cancer Research Center Started 2023Primary completion 2030-03 NCT05332561

    atezolizumabinavolisibipatasertibolaparibsacituzumab govitecantrastuzumabpertuzumab

    Arm 6 (Trastuzumab / Pertuzumab, ERBBB): HER2 exon-20 insertion, Activating HER2-mutation

    HER2 (ERBB2) activating mutationBRCA1/2 mutationEarly-stage Breast Cancer

  8. Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

    Active, not recruiting Phase 2 Gilead Sciences Started 2020Primary completion 2021-08 NCT04454437

    sacituzumab govitecan

    For individuals with a documented germ-line BRCA1/BRCA2 mutation who received an approved PARP inhibitor, the PARP inhibitor can be used to meet the crite…

    BRCA1/2 mutationMetastatic Triple-negative Breast Cancer